Please use this identifier to cite or link to this item:
Title: Identification of recent tuberculosis exposure using QuantiFERON-TB Gold Plus, a multicenter study.
Author: Pérez Recio, Sandra
Pallarès, Natàlia
Grijota Camino, Maria D.
Sánchez Montalvá, Adrián
Barcia, Laura
Campos Gutiérrez, Silvia
Pomar, Virginia
Rabuñal Rey, Ramón
Balcells, Maria Elvira
Gazel, Deniz
Montiel, Natalia
Vicente, Diego
Goić-Barišić, Ivana
Schön, Thomas
Paues, Jakob
Mareković, Ivana
Cacho Calvo, Juana
Barac, Aleksandra
Goletti, Delia
García Gasalla, Mercedes
Barcala, José Maria
Tórtola, María Teresa
Anibarro, Luis
Suárez Toste, Isabel
Moga, Esther
Gude Gonzalez, María J.
Naves, Rodrigo
Karslıgil, Tekin
Martin Peñaranda, Tania
Stevanovic, Goran
Trigo, Matilde
Rubio, Verónica
Karaoğlan,, Ilkay
Bayram, Nazan
Alcaide, Fernando
Tebé, Cristian
Santín Cerezales, Miguel
Keywords: Proves funcionals (Medicina)
Function tests (Medicine)
Issue Date: 10-Nov-2021
Publisher: American Society for Microbiology Press, Washington DC, USA,
Abstract: We investigated whether the difference of antigen tube 2 (TB2) minus antigen tube 1 (TB1) (TB22TB1) of the QuantiFERON-TB gold plus test, which has been postulated as a surrogate for the CD81 T-cell response, could be useful in identifying recent tuberculosis (TB) exposure. We looked at the interferon gamma (IFN-g) responses and differences in TB2 and TB1 tubes for 686 adults with QFT-plus positive test results. These results were compared among groups with high (368 TB contacts), low (229 patients with immune-mediated inflammatory diseases [IMID]), and indeterminate (89 asylum seekers or people from abroad [ASPFA]) risks of recent TB exposure. A TB22TB1 value .0.6 IU ml21 was deemed to indicate a true difference between tubes. In the whole cohort, 13.6%, 10.9%, and 11.2% of cases had a TB2.TB1 result in the contact, IMID, and ASPFA groups, respectively (P = 0.591). The adjusted odds ratios (aORs) for an association between a TB22TB1 result of .0.6 IU ml21 and risk of recent exposure versus contacts were 0.71 (95% confidence interval [CI], 0.31 to 1.61) for the IMID group and 0.86 (95% CI, 0.49 to 1.52) for the ASPFA group. In TB contact subgroups, 11.4%, 5.4%, and 17.7% with close, frequent, and sporadic contact had a TB2.TB1 result (P = 0.362). The aORs versus the close subgroup were 1.29 (95% CI, 0.63 to 2.62) for the frequent subgroup and 1.55 (95% CI, 0.67 to 3.60) for the sporadic subgroup. A TB22TB1 difference of .0.6 IU ml21 was not associated with increased risk of recent TB exposure, which puts into question the clinical potential as a proxy marker for recently acquired TB infection.
Note: Reproducció del document publicat a:
It is part of: Microbiology Spectrum, 2021, vol. 9 , num. 3
Related resource:
ISSN: 2165-0497
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
716161.pdf1.13 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons